These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1900236)
21. The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain. Marquette KA; Pittman DD; Kaufman RJ Blood; 1995 Oct; 86(8):3026-34. PubMed ID: 7579396 [TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of different activated forms of factor VIII, the human antihemophilic A factor. Bihoreau N; Sauger A; Yon JM; Van de Pol H Eur J Biochem; 1989 Oct; 185(1):111-8. PubMed ID: 2509202 [TBL] [Abstract][Full Text] [Related]
23. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. Nogami K; Shima M; Hosokawa K; Nagata M; Koide T; Saenko EL; Tanaka I; Shibata M; Yoshioka A J Biol Chem; 2000 Aug; 275(33):25774-80. PubMed ID: 10831589 [TBL] [Abstract][Full Text] [Related]
24. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor. Oh HK; Lee JM; Byun TH; Park SY; Kim YH Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450 [TBL] [Abstract][Full Text] [Related]
25. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Eaton D; Rodriguez H; Vehar GA Biochemistry; 1986 Jan; 25(2):505-12. PubMed ID: 3082357 [TBL] [Abstract][Full Text] [Related]
26. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII. Mikkelsen J; Thomsen J; Ezban M Biochemistry; 1991 Feb; 30(6):1533-7. PubMed ID: 1899619 [TBL] [Abstract][Full Text] [Related]
27. Role of the B domain for factor VIII and factor V expression and function. Pittman DD; Marquette KA; Kaufman RJ Blood; 1994 Dec; 84(12):4214-25. PubMed ID: 7994036 [TBL] [Abstract][Full Text] [Related]
28. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896 [TBL] [Abstract][Full Text] [Related]
29. The size of human factor VIII heterodimers and the effects produced by thrombin. Fay PJ; Anderson MT; Chavin SI; Marder VJ Biochim Biophys Acta; 1986 Jun; 871(3):268-78. PubMed ID: 3085715 [TBL] [Abstract][Full Text] [Related]
30. Identification of the thyrotropin-releasing hormone-prohormone and its posttranslational processing in a transfected AtT20 tumoral cell line. Nillni EA; Sevarino KA; Jackson IM Endocrinology; 1993 Mar; 132(3):1260-70. PubMed ID: 8440187 [TBL] [Abstract][Full Text] [Related]
33. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors. D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645 [TBL] [Abstract][Full Text] [Related]
34. B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Röstin J; Smeds AL; Akerblom E Bioconjug Chem; 2000; 11(3):387-96. PubMed ID: 10821655 [TBL] [Abstract][Full Text] [Related]
35. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Nord K; Nord O; Uhlén M; Kelley B; Ljungqvist C; Nygren PA Eur J Biochem; 2001 Aug; 268(15):4269-77. PubMed ID: 11488921 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of biologically active deletion mutants of human factor VIII:C. Langner KD; Bird RE; McCandliss R; Huber B; Amann E; Zettlmeissl G; Küpper HA Behring Inst Mitt; 1988 Apr; (82):16-25. PubMed ID: 3136764 [TBL] [Abstract][Full Text] [Related]
37. Proteolytic degradation of microtubule associated protein tau by thrombin. Olesen OF Biochem Biophys Res Commun; 1994 Jun; 201(2):716-21. PubMed ID: 8003007 [TBL] [Abstract][Full Text] [Related]
38. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Eaton DL; Wood WI; Eaton D; Hass PE; Hollingshead P; Wion K; Mather J; Lawn RM; Vehar GA; Gorman C Biochemistry; 1986 Dec; 25(26):8343-7. PubMed ID: 3030393 [TBL] [Abstract][Full Text] [Related]
39. Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII. Geng JP; Castellino FJ Thromb Haemost; 1997 May; 77(5):926-33. PubMed ID: 9184404 [TBL] [Abstract][Full Text] [Related]
40. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain. Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]